Research/Review: Structure and Linkage Disequilibrium Analysis of Adamantane Resistant Mutations in Influenza Virus M2 Proton Channel
The M2 proton channel is translated by the M gene segment of influenza viruses, and has been adopted as an attractive target for influenza A viruses, on which a series of adamantane-based drugs act. However, recently epidemic influenza viruses have had strong resistant effects against the adamantane-based drugs. In this paper, we combined evolutionary analyses, linkage disequilibrium as well as molecular dynamics simulations to explore the drug resistance of the M2 proton channel, with an aim of providing an in-depth understanding of the resistant mechanism for adamantane-based drugs. We collected 2746 coding sequences for swine, avian, and human M2 proteins. After evolutionary and linkage disequilibrium analyses, we found that the some residues in the C-terminal were associated with the famed resistant mutation S31N. Subsequently, we constructed the 3D structures of the swine, avian as well as human M2 channel, and performed MD simulations on these channels with a typical adamantane-based drug rimantadine. From the simulation trajectories, we found that the resistance against the adamantane-based drugs for the M2 channel from 2009 A(H1N1) viruses was derived from the structural allostery in the transmembrane and C-terminal regions. The helices in the transmembrane region were irregular in formation and employed larger distances between the adjacent 2 helices, which can weaken the interactions between the adjacent 2 helices and destabilize the helix-helix assembly, resulting in a comparatively loosely structure. The helices in the C-terminal region show a disordered configuration, giving chances for solvent molecules to enter into the channel pore.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: June 1, 2014
More about this publication?
- Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites